iBio, Inc. (IBIO) earnings
IBIO earnings moved a median of -2.46% by the close. Quarterly and annual IBIO reports and results, each read against the price at its own news timestamp. Back to the IBIO overview →
18 measured IBIO earnings events.
Where these IBIO earnings landedvs 17 measured IBIO earnings reactions
| Middle 50% of IBIO earnings reactions | -4.32% to +0.04% |
|---|---|
| Median reaction (to close) | -2.46% |
| Measured reactions | 17 |
Point-in-time · zero look-ahead
Half of the 17 IBIO earnings events with a measured close landed between -4.32% and +0.04%; 29% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-K iBio, Inc. For: Jun 30 | SEC filing · Form 10-K | -2.82% | -4.22% | |
| Form 10-Q iBio, Inc. For: Mar 31 | SEC filing · Form 10-Q | -2.47% | -4.32% | |
| Form 10-Q iBio, Inc. For: Dec 31 | SEC filing · Form 10-Q | -4.93% | -4.74% | |
| Form 10-Q/A iBio, Inc. For: Sep 30 | SEC filing · Form 10-Q | -0.43% | -5.17% | |
| Form 10-Q iBio, Inc. For: Sep 30 | SEC filing · Form 10-Q | -3.22% | — | |
| Form 10-K iBio, Inc. For: Jun 30 | SEC filing · Form 10-K | -0.77% | +1.73% | |
| Form 10-Q iBio, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.00% | +0.00% | |
| iBio Reports Fiscal Third Quarter 2025 Financial Results | Press release | +0.00% | +0.00% | |
| Form 10-Q iBio, Inc. For: Dec 31 | SEC filing · Form 10-Q | +0.00% | -2.46% | |
| iBio Reports Fiscal Second Quarter 2025 Financial Results | Press release | +0.00% | -2.46% | |
| Form 10-Q iBio, Inc. For: Sep 30 | SEC filing · Form 10-Q | -0.39% | -9.02% | |
| iBio Reports Fiscal First Quarter 2025 Financial Results | Press release | -0.39% | -9.02% | |
| Form 10-K/A iBio, Inc. For: Jun 30 | SEC filing · Form 10-K | — | -1.09% | |
| Form 10-K iBio, Inc. For: Jun 30 | SEC filing · Form 10-K | +2.62% | -3.14% | |
| Form 10-Q iBio, Inc. For: Mar 31 | SEC filing · Form 10-Q | -0.55% | +3.87% | |
| iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update | Press release | -0.55% | +3.87% | |
| Form 10-Q iBio, Inc. For: Dec 31 | SEC filing · Form 10-Q | +1.72% | +4.31% | |
| Form 10-Q iBio, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.00% | +0.04% |
Keep exploring
More IBIO: analyst actions → · SEC filings → · IBIO overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Relmada Therapeutics, Inc. (RLMD) | 265 | -0.01% | 44% |
| HUTCHMED (China) Limited - American Depositary Shares (HCM) | 263 | 0.00% | 47% |
| NOVUS THERAPEUTICS (NVUS) | 263 | -0.14% | 40% |
| Haemonetics Corporation (HAE) | 261 | -0.07% | 44% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.